Press

2020-07-10

Fraktalkine pathway mechanism of action for Kancera drug candidate KAND567 is linked to reduced risk of serious complications in COVID-19

Preparation for a clinical study with KAND567 in COVID-19 patients now under way Kancera AB (Nasdaq First North Premier Growth Market: KAN) today announces that independent researchers have published results showing that the fraktalkine system is activated in Covid-19...

Read More
2020-06-15

Kancera’s drug candidate KAND567 has a positive effect on mobility in a preclinical model of spinal cord injury

Kancera AB (Nasdaq First North Premier Growth Market: KAN) announces that an independent research group has published results showing that the company's drug candidate KAND567 has a protective effect on nerve tissue and its function in a preclinical disease...

Read More
2020-06-10

Interim report for the first quarter 2020, 1 januari-31 March 2020 Kancera AB (publ.), org.nr. 556806-8851.

First quarter in brief 1 January – 31 March 2020 Net sales for the period (January to March) amounted to SEK 0,04 million (3,1). R&D costs for the period amounted to SEK 9,7 million (10,2). Operating profit for the...

Read More
2020-05-14

Kancera applies for a Phase II study with KAND567 in covid-19 patients

This is a translation of a press release in Swedish dated 2020-05-13 Kancera today announces that the company has submitted an application to the Swedish Medicines Agency for permission to conduct a phase II clinical study of the drug...

Read More
2020-03-06

Kancera provides an update on the development of the drug candidate KAND145

Kancera AB (Nasdaq First North Premier Growth Market: KAN) today provides an update on the development of the drug candidate KAND145. Results from the ongoing patenting process underscores the level of innovation of KAND145. In addition, positive clinical results...

Read More
2020-03-06

Kancera reports positive results from the final part of the phase Ib program for KAND567

Kancera AB (Nasdaq First North Premier Growth Market: KAN) today announces that results from the Phase Ib program for KAND567 show that the drug candidate is well tolerated by intravenous administration. Kancera will now compile an application for permission...

Read More
2020-03-02
2020-02-05

Kancera has received approval to start the final part of the phase Ib program for KAND567

Kancera AB (Nasdaq First North Premier Growth Market: KAN) today announces that it has received approval from the Finnish Medicines Agency Fimea and the Ethics Committee to start the final part of the phase Ib program for KAND567. The...

Read More
2019-12-04

Kancera reports in-depth analysis of the Phase Ib program with KAND567, showing the desired effect on the human immune system

Kancera AB (Nasdaq First North Growth Market: KAN) reports results from an in-depth immunological analysis of blood samples from healthy subjects in the ongoing Phase Ib program. The analysis shows that KAND567 effectively blocks certain specific immune cells that...

Read More
2019-11-26

Interim report for the third quarter 2019, 1 January – 30 September 2019

Third quarter in brief 1 July – 30 September 2019 Net sales for the period (January to September) amounted to SEK 3,3 Million (0,1 Million) of which the third quarter contributed SEK 0,2 Million (0,0 Million). R&D costs for...

Read More